View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Mixed Signals, Reasons for Caution The S&P 500 uptrend remains intact, and the same can be said for the QQQ's. Despite a positive view of these two metrics, the aspect of of failed U.S. dollar breakdown coupled with the reversal. of the 10-year yields higher does give us pause. The S&P 500 breadth is showing signs of breadth divergence. 1.) The U.S. dollar has staged a false breakdown and is now on the cusp of a reversal. A decisive close through last Friday's close of 104.89 could yet negate t...

 PRESS RELEASE

Penns Woods Bancorp, Inc. Amends CEO Grafmyre Contract

Penns Woods Bancorp, Inc. Amends CEO Grafmyre Contract WILLIAMSPORT, Pa., June 04, 2024 (GLOBE NEWSWIRE) -- Penns Woods Bancorp, Inc. (NASDAQ:PWOD) announced today that a mutual agreement has been reached with its Chief Executive Officer, Richard A. Grafmyre CFP®, to amend Mr. Grafmyre’s employment agreement. The amendment was agreed upon after conducting a review of reported compensation data for the Company’s peer group, industry compensation analysis, and discussions with shareholders. The amendment, effective June 3, 2024 removes the provision for Mr. Grafmyre to be compensated for un...

 PRESS RELEASE

Lumos Pharma Announces New Analyses of Phase 2 OraGrowtH212 Trial Pres...

Lumos Pharma Announces New Analyses of Phase 2 OraGrowtH212 Trial Presented at ENDO 2024 AUSTIN, Texas, June 04, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced today details of new analyses of data from its Phase 2 OraGrowtH212 clinical trial presented in two posters at the , held in Boston, MA, June 1-4, 2024. The posters were presented in parallel sessions on Monday June 3, 2024. “The new analyses of data from our OraGrowtH212 Trial further characterized LUM-201’s unique ability to augment the nat...

 PRESS RELEASE

Capital City Bank Group, Inc. Announces Cash Dividend

Capital City Bank Group, Inc. Announces Cash Dividend TALLAHASSEE, Fla., May 30, 2024 (GLOBE NEWSWIRE) -- The Board of Directors of Capital City Bank Group, Inc. (NASDAQ: CCBG) declared a quarterly cash dividend on its common stock of $0.21 per share. The dividend produces an annualized rate of $0.84 per common share and is payable on June 24, 2024 to shareowners of record as of June 10, 2024. The annualized dividend yield is 3.14% based on a closing stock price of $26.74 on May 29, 2024. About Capital City Bank Group, Inc.Capital City Bank Group, Inc. (NASDAQ: CCBG) is one of the larges...

 PRESS RELEASE

Penns Woods Bancorp, Inc. Announces Quarterly Dividend

Penns Woods Bancorp, Inc. Announces Quarterly Dividend WILLIAMSPORT, Pa., May 28, 2024 (GLOBE NEWSWIRE) -- Richard A. Grafmyre CFP®, Chief Executive Officer of Penns Woods Bancorp, Inc., (NASDAQ:PWOD) has announced that the Company’s Board of Directors declared a second quarter 2024 cash dividend of $0.32 per share. The dividend is payable June 25, 2024 to shareholders of record June 11, 2024. About Penns Woods Bancorp, Inc. Penns Woods Bancorp, Inc. is the bank holding company for Jersey Shore State Bank and Luzerne Bank. The banks serve customers in North Central and North Eastern P...

 PRESS RELEASE

Penns Woods Bancorp, Inc. Announces Stock Repurchase Program

Penns Woods Bancorp, Inc. Announces Stock Repurchase Program WILLIAMSPORT, Pa., May 28, 2024 (GLOBE NEWSWIRE) -- Richard A. Grafmyre, CEO of Penns Woods Bancorp, Inc., (NASDAQ: PWOD) (“Company”) has announced that the Company’s Board of Directors has authorized the repurchase of up to 5% of the outstanding shares of the Company. The repurchase plan is for a one-year period ending May 31, 2025 and allows for the repurchase of up to 376,000 shares. The repurchase plan replaces the existing previously authorized repurchase plan, which expires on May 31, 2024. Repurchases are authorized to ...

 PRESS RELEASE

Capital City Bank Group, Inc. Receives Notification of Deficiency From...

Capital City Bank Group, Inc. Receives Notification of Deficiency From NASDAQ Related to Delayed Filing of Quarterly Report on Form 10-Q TALLAHASSEE, Fla., May 24, 2024 (GLOBE NEWSWIRE) -- Capital City Bank Group, Inc. (the “Company”) today announced that it received on May 21, 2024 a notice from the Nasdaq Stock Market LLC (“Nasdaq”) stating that, as a result of not having timely filed its Quarterly Report on Form 10-Q for the quarter ended March 31, 2024 (the “Form 10-Q”), the Company is no longer in compliance with the continued listing requirements of Nasdaq Listing Rule 5250(c)(1), w...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

Moody's Ratings assigns Baa2 to Molson Coors' euro notes; outlook posi...

Moody's Ratings (Moody's) today assigned Baa2 ratings to the gtd senior unsecured euro notes offered by Molson Coors Beverage Company ("Molson Coors"). The proceeds will be used for general corporate purposes including refinancing the €800 million gtd senior unsecured Euro notes due in July 2024. Mo...

 PRESS RELEASE

Lumos Pharma Announces Abstracts Accepted for Presentation at ENDO 202...

Lumos Pharma Announces Abstracts Accepted for Presentation at ENDO 2024 AUSTIN, Texas, May 20, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that new analyses of data from its Phase 2 OraGrowtH210 and OraGrowtH212 clinical trials have been accepted for presentation in two posters at the , to be held in Boston, MA June 1-4, 2024. Poster Session P069 – Monday June 3, 12:00-1:30 PM ET : Oral LUM-201 Restores Pulsatile Growth Hormone Secretion and Growth Response in Moderate Pediatric Growth Ho...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

 PRESS RELEASE

Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA and Re...

Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA and Reports First Quarter 2024 Financial Results Outcome from End-of-Phase 2 Meeting Supportive of a Placebo-Controlled Phase 3 Trial Updated 12 and 24-Month Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials Continue to Show Oral LUM-201 Achieves Significant Increase in Growth from Baseline, Durable Effect to 24 Months Company to Host Conference Call May 15, 2024, at 8:30AM ET AUSTIN, Texas, May 14, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on therap...

 PRESS RELEASE

Lumos Pharma to Report First Quarter 2024 Financial Results and Provid...

Lumos Pharma to Report First Quarter 2024 Financial Results and Provide Clinical Update on May 15, 2024 AUSTIN, Texas, May 09, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:LUMO), a late-stage biopharmaceutical company focused on therapeutics for rare diseases, announced it will report first quarter 2024 financial results before market open on Wednesday, May 15, 2024. The company will host a conference call and webcast at 8:30 AM ET that day to discuss these financial results and provide an update on clinical and corporate activities. A question-and-answer session will follow the prepared remarks. ...

Penns Woods Bancorp Inc: 2 directors

A director at Penns Woods Bancorp Inc bought 500 shares at 18.677USD and the significance rating of the trade was 34/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years ...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: May 4, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch